OBJECTIVE: To analyze differences in cytology and histology results between patients previously vaccinated against human papillomavirus (HPV) compared with unvaccinated patients who presented to an academic colposcopy clinic for evaluation of abnormal cervical cytology.
RESULTS:
In multivariable analyses, women who previously received at least one dose of the HPV vaccine had 53% (adjusted odds ratio [OR] 0.47, 95% confidence interval [CI] 0.34-0.66; P,.001) lower odds of presenting with high-grade cytology (adenocarcinoma in situ, atypical glandular cells, atypical squamous cells cannot rule out high grade, and high-grade squamous intraepithelial lesion) and 36% (adjusted OR 0.64, 95% CI 0.48-0.85; P5.002) lower odds of presenting with cervical intraepithelial neoplasia 2 or 3 or worse histology compared with unvaccinated women.
CONCLUSION:
Patients presenting for colposcopic evaluation of abnormal cytology who had previously received the HPV vaccine had fewer high-grade lesions on both cytology and histology when compared with HPV-unvaccinated women. 
LEVEL OF EVIDENCE: II

I
nfection with human papillomavirus (HPV) is associated with the development of cancer of the cervix, vagina, vulva, and anogenital area in addition to genital warts in women. 1, 2 The American Cancer Society estimates that in 2015, 12,900 new cases of cervical cancer will be diagnosed and 4,100 deaths will occur in the United States. 3 Human papillomavirus 16 and 18 are associated with approximately 70% of cervical cancer cases. 4 In clinical trials, quadrivalent (which targets HPV 16 or 18 and 6 or 11) and bivalent vaccines (which target HPV 16 and 18) are highly efficacious in significantly reducing the development of precancerous cervical lesions including: cervical intraepithelial neoplasia (CIN) 1, CIN 2-3, and adenocarcinoma in situ in HPV-naïve women. [5] [6] [7] The quadrivalent vaccine also successfully reduces the development of precancerous cervical lesions in women previously exposed to one of the HPV types 6, 11, 16, and 18. 8 Although clinical efficacy trials are essential to demonstrate the usefulness of clinical interventions such as vaccines, the actual success or clinical effectiveness of an intervention is measured by the performance in routine clinical settings and its subsequent effect on public health. Although an abundance of clinical efficacy data exists from study trials, limited data have been published on the effectiveness of the quadrivalent and bivalent HPV vaccines in clinical practice.
Given the paucity of data available from clinical settings, as opposed to clinical trials, we sought to evaluate the severity of cervical cytology abnormalities and pathologic abnormalities among previously HPV-vaccinated and unvaccinated women presenting for colposcopic examination at an academic center.
MATERIALS AND METHODS
This study was approved by the Partners Healthcare institutional review board at Brigham and Women's Hospital (Boston, Massachusetts). We analyzed patients from the Center for Lower Genital Tract Disease at two institutions in Boston, Massachusetts, using an electronic patient registry that was created in 2006 to collect demographic, clinical, and outcome information from women with abnormal cervical cytology or HPV tests referred for colposcopy at an academic teaching clinic. The methods for this registry have previously been described. 9 Briefly, women are referred to this clinic for evaluation or management of abnormal cervical cytology or HPV tests. A standardized paper form containing demographics, HPV vaccine status, comorbidities, reproductive history, and lifestyle factors is completed by the patient, reviewed by a nurse or a physician, and entered into the database prospectively at each visit. Counseling opportunities and content are also documented on related topics such as: cervical cytology, HPV, colposcopy, treatment options, smoking cessation, and the HPV vaccine. Patients then undergo a standard colposcopic examination by the resident and a dedicated colposcopy expert (attending physician) or the by expert alone and directed biopsies and endocervical curettage are obtained if indicated.
A dedicated team of gynecologic pathologists reviews cervical cytology and pathology specimens obtained from elsewhere and these results are entered prospectively into our database by a nurse or physician. The same team of gynecologic pathologists reviews cervical cytology and pathology specimens collected during the visit and these results (HPV, cervical cytology, or pathology) are subsequently entered into the electronic database by a nurse. Patients are then managed by either the 2006 or by modified 2012 American Society for Colposcopy and Cervical Pathology guidelines, depending on when they presented for evaluation. [10] [11] [12] Modification of 2012 guidelines entails one baseline colposcopy for women aged 21-24 years presenting with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology. Patients are then triaged according to their pathology results with low-grade or normal results following up with repeat cytology in 1 year and patients with highgrade squamous intraepithelial lesions or worse following standard guidelines. This approach allows us to confirm the presence or absence of severe histologic abnormalities before triage. All entered data are saved for research purposes and the attending physician attests to its validity before signing the note. The information is then automatically merged into the electronic clinical record.
Women were included in the analysis if they were seen between February 26, 2007, and March 10, 2014, and were age 26 years or younger at their first appointment to include all women in the U.S. Food and Drug Administration (FDA)-approved age range for the quadrivalent vaccine approved in 2006. Women were excluded if they did not have a cytology and histology result listed in the database. Women were also excluded if they were unsure of their HPV vaccination date.
Patient characteristics from the first visit were used when patients had more than one visit. Contraception methods were grouped into mutually exclusive categories including hormonal contraception (birth control pills, patches, Depo Provera, and vaginal rings), barrier, long-acting reversible contraception (intrauterine devices, Nexplanon or Implanon), tubal ligation, none, and other. Women who reported both hormonal contraception and barrier use were grouped into the appropriate hormonal category. The patient form included an open-ended field for other medical illnesses, which allowed for reporting of a large number of medical conditions. We dichotomized this variable to any or no report of a medical illness.
We selected the worst cytology and histology result for each patient and selected results only after vaccination for vaccinated patients. Cervical cytology and histology results were grouped into dichotomous variables to compare women who presented with high-grade lesions and low-grade lesions. Low-grade cytology included negative for intraepithelial lesion or malignancy, atypical squamous cells of undetermined significance, and low-grade squamous intraepithelial lesions. High-grade cytology included high-grade squamous intraepithelial lesions, atypical squamous cells-cannot rule out high-grade squamous intraepithelial lesions, atypical glandular cells, and adenocarcinoma in situ. Low-grade histology included normal and CIN 1 and high-grade histology included CIN 2-3, adenocarcinoma in situ, and adenocarcinoma or squamous cell carcinoma.
Patient characteristics were compared by lowgrade and high-grade cytology and histology to identify factors associated with poorer outcomes. We used x 2 and Fisher's exact tests for categorical variables and t tests for continuous variables. P values ,.05 were considered statistically significant. To examine the associations between vaccination and high-grade cytology and histology, we ran unconditional multivariable logistic regression models and calculated adjusted odds ratios (OR) and 95% confidence intervals (CIs). We adjusted for factors found to be associated with high-grade cytology and histology in the preliminary analyses. For cytology, these included race-ethnicity, language, number of pregnancies, gonorrhea, and smoking status. For histology, we adjusted for race-ethnicity, language, number of pregnancies, and smoking status. To prevent records with missing covariates from being dropped from analyses, a category for missing values was created for each variable with missing data and an indicator for this category was included in the models. 13 Statistical analysis was performed using SAS 9.2.
RESULTS
There were 1,662 women in the desired age range, of whom 27 were excluded because they could not remember the date when they received the HPV vaccine and 243 were excluded because they had no cervical cytology or histology results in the database. The final sample size was 1,392, which included 481 HPV-vaccinated women and 911 HPV-unvaccinated women. The average age of the entire cohort was 22.8 years old. The average age that women received their first dose of the HPV vaccine was 20.4 years old.
Baseline demographics and patient characteristics were analyzed to evaluate women with low-grade lesions and high-grade lesions for both cytology and histology results (Table 1 ). Significant differences, defined as a P,.05, were noted between the lowgrade and high-grade groups for cytology with respect to race-ethnicity, language, pregnant at initial visit, number of pregnancies, gonorrhea, and smoking history. With respect to histology, significant differences were noted between the low-grade and high-grade groups for race-ethnicity, language, number of pregnancies, HPV status, and smoking status.
When comparing worst cytology results between women who received at least one dose of the HPV vaccine and those who were never vaccinated, we found a significant difference between outcomes (Table 2 ). For example, unvaccinated women were approximately three times more likely to present with a high-grade squamous intraepithelial lesion (16.3% compared with 5.8%) on cytology. When we evaluated cytology as a dichotomous outcome, significantly more women in the unvaccinated group presented with high-grade cytology (21.7% compared with 10.8%, P,.001).
Analyses of the cervical histology results were similar to the cytology results. Women who were unvaccinated were more likely to have CIN 2-3 lesions (26.4% compared with 17.3%). When we utilized a dichotomous outcome to compare women with CIN 2-3 or worse (CIN 2-3, adenocarcinoma in situ, adenocarcinoma, or squamous cell carcinoma) compared with CIN 1 or less, women in the unvaccinated cohort were significantly more likely to be diagnosed with CIN 2-3, adenocarcinoma in situ, or invasive cancer (28.2% compared with 18.7%, P,.001).
Multivariable analysis was carried out to further evaluate cytology results in HPV-vaccinated and unvaccinated women (Table 3) . After adjusting for confounders, women who received at least one dose of the HPV vaccine had 53% lower odds of presenting with high-grade cytology (adjusted OR 0.47, 95% CI 0.34-0.66; P,.001). Multivariable analysis was also carried out to evaluate histology results after colposcopy (Table 4) . After adjusting for confounders, women who received at least one dose of the HPV vaccine had 36% lower odds of presenting with CIN 2-3, adenocarcinoma in situ, or invasive cancer compared with women who did not received the HPV vaccine (adjusted OR 0.64, 95% CI 0.48-0.85; P5.002). We repeated our analysis restricting the HPV-vaccinated group to women who received all three doses and compared them with unvaccinated women and found similar results. Women who received all three doses of the HPV vaccine had 39% lower odds of presenting with a high-grade histology result (adjusted OR 0.61, 95% CI 0.44-0.85; P5.003) and 48% lower odds of presenting with a high-grade cytology result (adjusted OR 0.52, 95% CI 0.36-0.76; P5.008) than unvaccinated women.
DISCUSSION
In this study of clinical effectiveness, we found that prior HPV vaccination leads to significant reductions in high-grade cytologic lesions as well as CIN 2-3, adenocarcinoma in situ, or worse histologic lesions in women presenting for colposcopic evaluation of abnormal cervical cytology.
Our data contribute new information to the available HPV vaccine clinical effectiveness data by focusing on cytologic and histologic results, which determine management strategies, instead of epidemiologic outcomes such as incidence of condyloma, measurement of Unauthorized reproduction of this article is prohibited.
HPV prevalence in the population, and populationbased proportion of CIN 2 or worse lesions of HPV vaccine subtypes. [14] [15] [16] Although these alternative markers of vaccine success are important, severity of cytology and histology may affect management and thus morbidity NILM, negative for intraepithelial lesion or malignancy; CIN, cervical intraepithelial neoplasia; LARC, long-acting reversible contraception; STI, sexually transmitted infection; HPV, human papillomavirus; HIV, human immunodeficiency virus. Data are mean6standard deviation or n (%). * Low-grade cytology includes low-grade squamous intraepithelial lesion and atypical squamous cells of undetermined significance; highgrade cytology includes adenocarcinoma in situ, atypical glandular cells, high-grade squamous intraepithelial lesions, and atypical squamous cells-cannot rule out high-grade squamous intraepithelial lesions; CIN 2-3 or worse includes invasive cancer and adenocarcinoma in situ. † Data were missing for race (n549), marital status (n511), language (n532), insurance status (n523), concerns about insurance (n5150), sexual partners (n564), medical conditions (n59), pregnancy at initial visit (n512), number of pregnancies (n514), birth control (n558), and smoking status (n55). ‡ These factors differed between cervical cytology groups (P,.05). § These factors differed between cervical histology groups (P,.05). ∥ The number of lifetime sexual partners on the patient questionnaire was modeled using the following categories: 1-3, 3-5, 7-10, $10 partners. The overlap and missing number of six was an error that was uncorrected during the first year of data collection and therefore, data collection for this variable continued in this manner for consistency. [17] [18] [19] [20] Furthermore, even in women who do require cervical treatment for high-grade cervical pathology, prior administration of the quadrivalent HPV vaccine resulted in 46.2% reduction in subsequent HPV-related disease and 64.9% risk reduction of subsequent high-grade disease compared with unvaccinated women, thereby decreasing the number of subsequent colposcopic evaluations and treatments they might need. 21 This study has several notable strengths. The Center for Lower Genital Tract Disease registry was created the same year that the quadrivalent vaccine was approved by the FDA for clinical use. This provides a prospective and comprehensive collection tool to analyze demographics and characteristics of women based on HPV vaccination status. The Center for Lower Genital Tract Disease is also a major referral center in New England leading to a relatively diverse study population. This creates a unique opportunity to understand the relationship of HPV vaccination status, demographics, and patient characteristics to cervical pathology results, which can assist with guiding clinical practice management decisions.
This analysis has several limitations. Although the data from cytology and histology specimens are objective, the vaccination information is collected by self-report. However, we do not feel that this would introduce recall bias because it is unlikely that a patient would misremember whether she was vaccinated or not in a systematically biased way, and we controlled for demographic factors in our analysis. Additionally, many different clinicians enter data into the registry, which may result in data entry error, but each entry is reviewed and confirmed by one of the specialized attending physicians to further validate the data and ensure accuracy. NILM, negative for intraepithelial lesion or malignancy; OR, odds ratio; CI, confidence interval. Data are n (%) unless otherwise specified. * Low-grade includes low-grade squamous intraepithelial lesions and atypical squamous cells of undetermined significance; high-grade includes adenocarcinoma in situ, atypical glandular cells, high-grade squamous intraepithelial lesions, and atypical squamous cellscannot rule out high-grade squamous intraepithelial lesions. † Adjusted for race, language, number of pregnancies, gonorrhea, and smoking status. 
